-
- Description: Amarillo Biosciences, Inc. (Abi) is engaged in developing biologics for the treatment of human and animal diseases. The Company is focusing its research on human health indications for the use of low-dose orally administered natural human interferon alpha, particularly for the treatment of Sjogren's syndrome, Behcet's disease, polycythemia vera, essential thrombocythemia, idiopathic pulmonary fibrosis and oral warts in human immunodeficiency virus-positive (Hiv+) patients. Abi owns or licenses 15 United States patents relating to the use or composition of low-dose oral natural interferon alpha. Amarillo Biosciences, Inc. is a biotechnology company that specializes in the research and development of utilization of low-dose, orally administered interferon as a treatment for various conditions comprising chronic cough, influenza, and opportunistic infections in patients who are HIV positive. General Information Year established 1994
- More Products No Keyword available...
- About Owner No Owner Type Present...
-
